Yeast infection & Candida research and evidence

Inspect the maintained evidence map for recurrent vaginal symptoms.

See outcome-specific evidence on congenital malformations, miscarriage, stillbirth, and neonatal death.

A spontaneous-report analysis raises hypotheses but cannot establish event rates, causality, or treatment risk.

See current treatment claims and the contextual S005 study within their exact population and limits.

Inspect the maintained evidence map for broad Candida explanations.

Network analysis of first-line options.

A large cohort estimates malformation outcomes after first-trimester exposure; findings sit alongside broader pregnancy-outcome evidence.

One small Thai trial compares two single-dose vaginal treatments; wide confidence intervals do not establish equivalence or rare pregnancy safety.

A Chinese placebo-controlled trial reports symptom and culture outcomes after one-day oral treatment; it did not compare the drug with azoles.

FAERS signals lack exposure denominators and cannot establish causality or risks of vaginal treatment.

One sponsor-funded short-term trial reports a product-specific result with unresolved count/percentage discrepancies; it did not compare with recommended azoles.

Interviews with 24 women with prior treatment failure and two gynecologists describe possible concerns, but do not estimate adherence or compare treatment routes.

A broad narrative review adds diagnostic and treatment context but reports no pooled treatment estimates or direct maintenance-route comparison.

A regional review reports prevalence estimates among women ages 15–49, with high heterogeneity and unresolved table-count discrepancies; it does not support a treatment change.

A narrative review maps selected resistant-VVC reports with varied methods and outcomes; it provides no pooled comparison or treatment recommendation.

Eight selected guidelines split between three and four episodes/year; the authors' proposed phenotype distinction is unvalidated and has no new clinical outcomes.

A systematic review of 12 studies describes possible mechanisms but includes no meta-analysis, treatment result, or validated individual recurrence prediction.

A single-laboratory evaluation compared Aptima with Gram stain and culture; detection alone does not establish that yeast caused symptoms.

One 2010 military-clinic kit study reported low sensitivity; it does not measure symptom-only self-attribution or current commercial tests.

A single-clinic accuracy study reports device-specific results but no patient outcomes; it does not change diagnostic guidance or practical action.

Review of options for recurrence.

Head-to-head maintenance comparison.

Patient-reported burden of recurrence.

Diagnostic experience study.

Australian interviews with 10 trial-screened women add patient-reported context; themes and recalled delays are not population estimates or treatment effects.

One clinic compared bacteria and metabolites in 31 RVVC, 28 VVC, and 29 selected healthy controls; associations do not establish cause or treatment targets.

Cochrane review of probiotic add-ons.

What consumer microbiome tests actually report.

A 72-day feeding series analyzed fecal fungi in 28 completers; it did not test Candida disease or treatment, and its participant prevalence figures conflict.

In 96 analyzed stool samples, recent carbohydrate intake correlated positively and saturated fat negatively with relative Candida abundance; usual-diet correlations were not significant. No effect size or clinical outcome was reported.

In 1,455 young adults, relative diet-pattern scores were associated with some cardiometabolic biomarkers, but matching to genotype added no benefit; no Candida or infection outcome was measured.

Nine human studies through 2024 tested yogurt or yogurt drinks; results varied, and some trials had attrition or reporting gaps. No Polish staples were studied.

Trial of nystatin for systemic symptom claims.

SIFO findings in referred patients.